ZYXI:OTCQB-Zynex Inc (USD)

COMMON STOCK | Medical Distribution | OTCQB - U.S. Registered

Last Closing

USD 12.58

Change

+0.23 (+1.86)%

Market Cap

USD 0.01B

Volume

0.12M

Analyst Target

USD 27.35
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Zynex Inc through its subsidiaries, designs, manufactures and sells U.S. Food and Drug Administration medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap
HSIC Henry Schein Inc

N/A

USD 9.40B
PDCO Patterson Companies Inc

N/A

USD 2.31B
EDAP EDAP TMS SA

N/A

USD 0.27B
YI 111 Inc

N/A

USD 0.09B
AHG Akso Health Group ADR

N/A

USD 0.09B
COSM Cosmos Health Inc.

N/A

USD 0.01B

ETFs Containing ZYXI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.52% 71% C- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.52% 71% C- 78% C+
Trailing 12 Months  
Capital Gain 7.06% 86% B+ 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.06% 71% C- 58% F
Trailing 5 Years  
Capital Gain 179.56% 100% F 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 179.56% 100% F 89% A-
Average Annual (5 Year Horizon)  
Capital Gain 18.10% 86% B+ 79% B-
Dividend Return 18.10% 86% B+ 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 63.30% 57% F 26% F
Risk Adjusted Return 28.59% 71% C- 65% D
Market Capitalization 0.01B 71% C- 59% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.